The intervention is use of a pediatric TMDS. Eligible children experiencing acute illness are examined over the phone by EMTs who follow a set of clinical guidelines to triage, assess, and develop treatment plans for participants. To evaluate the TMDS and as a safety measure EMTs will also examine most participants in-person a their homes following the phone exam.

MotoMeds pediatric telemedicine and medication delivery service (TMDS)

Participants enrolled in the control group will be recommended national exercise recommendations pertianing to engaging in 150 minutes a week of moderate intensity exercise five times per week.

Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing.

Patients in this group will receive available exercise recommendations of 150 minutes of moderate intensity exercise per week (30 minutes per day).

Exercise for Knee Osteoarthritis Recommendations (Control group)

Participants enrolled in the Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise will complete a total of two walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all). Each walking session will include 30-minute walking on a G-Trainer (AlterG Inc., Fremont, CA) under low-load walking conditions.

Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing.

Lower-body positive-pressure (LBPP) supported low-load treadmill walking exercise

Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking)

Participants enrolled in the aquatic exercise program will complete a total of two aquatic walking exercise sessions per week for a total of eight consecutive weeks (i.e. 16 exercise sessions in all). Each aquatic exercise program will include walking in the pool for 30 minutes at self-selected speeds under the guidance of an aquatic therapy instructor.

Apart from these exercise sessions participants in this group will complete 3 separate evaluation sessions at the beginning, interim, and end of the study where they will be walking on a standard-of care treadmill for 30 minutes with blood draws at 0 and 30 minutes (only during beginning and end session), kinematic measure of gait parameters, measures of different cardiovascular parameters and cardiometabolic markers followed by thigh muscle strength testing.

Exercise for Knee Osteoarthritis - (Aquatic Walking)

N=15 patients from 2025, in which management and treatment of arrhythmias and or myocardial dysfunction were driven by the panel

Determination of viral genome, bacterial serology, and markers of inflammation in pediatrics diagnosed with myocarditis

The 15 patients managed and treated for arrhythmias or myocardial dysfunction in 2024 without applying the myocarditis panel

Azienda Ospedaliero, Universitaria Ospedali Riuniti

Francesco Bianco, M.D., Ph.D., MSc., FEACVI

Federica Zallocco, M.D.

Bianca Lattanzi, M.D., Ph.D.

Alessia Omenetti, M.D., Ph.D.

Francesca C. Surace, M.D.

Emanuela Berton, M.D.

Alessandra Palpacelli, M.D.

Valentina Bucciarelli, M.D., Ph.D.

The first stage will be an "antigen-escalation" stage using a fixed total dose of cells (5 x 10\^6 cells/m\^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix.

Antigen-Escalation Stage

Each patient will receive 2 injections at the same dose (5 x 10\^6 cells/m2), 28 days apart, according to the following schedules:

Schedule One:

* Day 0: PRAME-specific T cells
* Day 28: PRAME- and SSX-specific T cells

Schedule Two:

* Day 0: PRAME- and SSX-specific T cells
* Day 28: PRAME/SSX/MAGE-specific T cells

Schedule Three:

* Day 0: PRAME/SSX/MAGE-specific T cells
* Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells

Schedule Four:

* Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells
* Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells

Antigen-Escalation Stage

In the dose escalation stage, three dose levels will be studied. Patients in the dose escalation portion of the study will be entered and stratified separately to the following two groups:

Group A: Patients receiving CTLs as therapy for Hodgkin's or non-Hodgkin's lymphoma.

Group B: Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.

Dose-Escalation Stage

Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:

DL1: Day 0 and Day 14: 5 x 10\^6 cells/m\^2

DL2: Day 0 and Day 14: 1 x 10\^7 cells/m\^2

DL3: Day 0 and Day 14: 2 x 10\^7 cells/m\^2

Dose-Escalation Stage

This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10\^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).

Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10\^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:

1. ANC \>1,000 or Platelets \>50,000 (or any other grade I AE attributable to aza)

   Adjustment: None
2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)

   Adjustment: 50% dose reduction
3. ANC \<500 or any episode of febrile neutropenia or platelets \<25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)

Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion

azacytidine and multiTAA T cells Stage

This phase will give patients \< 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.

Patients \< 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.

Pediatric multiTAA T cells Stage

The simultaneous vaccination group will receive routine childhood vaccinations and mRNA COVID-19 vaccination at Visit 1, followed by a health education visit without vaccination at Visit 2.

mRNA COVID-19 Vaccine

Routine Childhood Vaccinations

The sequential vaccination group will receive routine childhood vaccinations at Visit 1, followed by a health education visit with mRNA COVID-19 vaccination at Visit 2.

특발성 폐섬유증 환자에게 흡입하는 제논 가스를 활용한 MRI로 폐 기능 변화를 관찰하는 안전한 초기 연구입니다.

Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments

Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment

흡입 초분극 129 제논 가스를 사용하는 자기공명영상(MRI)이 승인된 IPF 치료를 받는 특발성 폐섬유증(IPF) 환자의 시간 경과에 따른 변화를 감지하기 위해 손상된 폐 기능을 시각화하는 데 도움이 될 수 있는지 여부

특발성 폐섬유증(IPF) 치료를 비교하는 과분극 129 제논 가스

제넨텍 제논 MRI 특발성 폐섬유증

Each participant is assigned a coordinating rheumatology nurse. Based on an initial bio-psycho-social assessment, the nurse and the participant define up to five activities using the Patient Specific Functional Scale (PSFS) and agree on goals based on shared decision-making. The coordinating nurse provides self-management support in face-to-face, telephone or online consultations depending on the participant's needs during the following six months. At each face-to-face consultation with the nurse, the PSFS activities and the goals are evaluated. Each participant can get up to 2.5 hours of support from the nurse, up to 4 hours a physiotherapist and or occupational therapist, and 1 hour from a social worker. In addition, the coordinating nurse helps identify relevant offers in the participant's municipality. The coordinating nurse can plan up to two conferences with involved professionals. A final consultation with the coordinating nurse is held after the six-month intervention.

A coordinating rheumatology nurse who follows the participant for six months, goal setting and action planning with the nurse, opportunity for needs based support from a physiotherapist, an occupational therapist and a social worker, opportunity for interdisciplinary conferences to coordinate support to achieve the agreed upon goals and a final status consultation.

Interdisciplinary Nurse-coordinated self-management support for people with inflammatory arthritis and substantial disease impact

Usual care consists of planned consultations every 6-12 months by a rheumatologist or a rheumatology nurse and access to support from a rheumatology nurse by telephone. The planned consultations encompass review of blood tests, joint examinations, review of completed answers to questionnaires in DANBIO, adherence and evaluation of whether pharmacological adjustment is necessary. In addition, the planned nursing consultations sporadically encompass education in relation to management of the disease, symptoms and the pharmacological treatment. At the outpatient departments at the Danish Hospital for Rheumatic Diseases, Rigshospitalet-Glostrup and Frederiksberg Hospital, patients who have specific challenges can be offered an additional nursing consultation for non-pharmacological support. At Rigshospitalet-Glostrup it is also possible to refer a patient to see a physiotherapist and/ or an occupational therapist in the outpatient department.

The Danish Center for Expertise in Rheumatology

Bente A Esbensen, PhD

Luise H Lindgren, PhD

Jette Primdahl, PhD

Berit F Petersen, MPQM

An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.

The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.

rheumatoid arthritis self-management program

The control group received general information on rheumatoid arthritis care and follow-up.

The first 15 subjects enrolled will receive the Td (tetanus diphtheria) vaccine at cycle 4 of IO therapy. The Td vaccine is administered as 0.5 mL intramuscular injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor.

Tetanus Diptheria Vaccine

Subjects 16 through 25 will receive the IPOL (polio booster) vaccine at cycle 4 of IO therapy. The IPOL vaccine is administered as 0.5 mL intramuscular or subcutaneous injection in the extremity (thigh or upper arm) in closest proximity to the largest tumor

Polio Boost Immunization

Carol Ann Wiggs, BSN

Participants in the usual care group receive standard pediatric care. In this study, participants in the Usual Care arm are a historical cohort of patients who meet eligibility criteria and are identified retrospectively from the Electronic Health Records. As such the investigators have registered this study on Clinical Trial.gov prior to the implementation of the active WE CARE experimental arm.

Standard pediatric care includes any existing screening practices, which can vary at each clinic.

Standard Pediatric Care

The study team will work with clinic staff and leadership to implement the WE CARE protocol at each clinical site.

The WE CARE System: A family-centered, highly efficacious approach for addressing adverse SDOH in the clinical setting. Arvin Garg, MD, MPH developed and conceptualized the WE CARE (Well-Child care visit, Evaluation, Community Resources, Advocacy, Referral, Education) intervention in 2005. This approach relies on existing clinical processes and infrastructure and social service resources, thereby making implementation, dissemination, and sustainability feasible. The intervention components include brief training of the clinical team; administration of a short screening tool to parents/patients identifying their desire for help with specific unmet social needs; and provider/clinic staff access to a physical or electronic family resource book containing community- resource listings. Providers generate referrals for families who indicate that they want help with unmet social needs on the WE CARE screener. Existing staff members may assist patients in connecting to referred resources.

WE CARE SDOH System

Arvin Garg, MD

Jennifer Hazelton

Susan Hogan, MD

Arvin Garg

Ron Adler, MD

Melanie Gnazzo, MD

중등도에서 중증 류마티스 관절염 환자를 대상으로 두 가지 약물 조합의 효과를 비교하는 시험입니다.

This intervention is open label. Both patient and investigator will know about the intervention. Participants are allocated according to block randomization. Total two groups with each contain 48 patients. One group will be given Tofacitinib, Methotrexate and another group will be given Upadacitinib, Methotrexate

To see the efficacy of Upadacitinib, Methotrexate versus Tofacitinib, Methotrexate in moderate to severe Rheumatoid arthritis

중등도에서 중증 류마티스 관절염에서 우파다시티닙, 메토트렉세이트와 토파시티닙, 메토트렉세이트의 효능을 비교하려면

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

MotoMeds 소아 원격진료 및 약물 배송 서비스(TMDS)

무릎 골관절염 운동 권장 사항(대조군), 무릎 골관절염 운동 - (LBPP 지원 저부하 트레드밀 걷기), 무릎 골관절염 운동 - (수중 걷기)

심근염 진단을 받은 소아에서 바이러스 게놈, 세균 혈청학 및 염증 표지자 결정

항원 증가 단계, 용량 증가 단계, 아자시티딘 및 다중 TAA T 세포 단계, 소아 다중 TAA T 세포 단계

mRNA COVID-19 백신, 정기적인 소아 예방 접종

제넨텍 제논 MRI 특발성 폐섬유증

염증성 관절염과 심각한 질병 영향을 가진 사람들을 위한 학제간 간호사가 조정하는 자기 관리 지원

류마티스 관절염 자가 관리 프로그램

파상풍, 디프테리아 백신, 소아마비 예방접종 강화

WE CARE SDOH 시스템, 표준 소아 진료

중등도에서 중증 류마티스 관절염에서 토파시티닙과 메토트렉세이트 병용 요법의 효능과 우파다시티닙과 메토트렉세이트 병용 요법의 효능 비교